SCHEMBL429276

SCHEMBL429276

NC(=O)CN1CCOCC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 1.00
HSD17B10 Q99714 2/20 0.61
ALOX15 P16050 1/20 0.59
TSHR P16473 1/20 0.59
SMN1; SMN2 Q16637 2/20 0.55
ALDH1A1 P00352 6/20 0.50
GLA P06280 1/20 0.47
GAA P10253 1/20 0.46
LMNA P02545 1/20 0.44
HTT P42858 2/20 0.43
MAPT P10636 1/20 0.43
MAPK1 P28482 1/20 0.43
USP2 O75604 2/20 0.43
ANPEP P15144 1/20 0.42
ATM Q13315 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16570813 1.00 KDM4E (1.00) KDM4EHSD17B10ALOX15TSHRSMN1; SMN2
Hydrochloric Acid SCHEMBL8859868 0.98 KDM4E (0.95) KDM4EHSD17B10ALOX15TSHRSMN1; SMN2
Hydrochloric Acid SCHEMBL16571085 0.98 KDM4E (0.95) KDM4EHSD17B10ALOX15TSHRSMN1; SMN2
Water SCHEMBL7425166 0.98 KDM4E (0.95) KDM4EHSD17B10ALOX15TSHRSMN1; SMN2
SCHEMBL11205570 0.98 KDM4E (1.00) KDM4EHSD17B10ALOX15TSHRSMN1; SMN2
SCHEMBL13833218 0.98 KDM4E (1.00) KDM4EHSD17B10ALOX15TSHRSMN1; SMN2
Hydrochloric Acid SCHEMBL2674609 0.98 KDM4E (0.95) KDM4EHSD17B10ALOX15TSHRSMN1; SMN2
Ethylamine SCHEMBL4594600 0.92 KDM4E (0.84) KDM4EHSD17B10ALOX15TSHRSMN1; SMN2
SCHEMBL17996821 0.90 KDM4E (0.81) KDM4EHSD17B10ALOX15TSHRSMN1; SMN2
SCHEMBL15867648 0.88 KDM4E (0.81) KDM4EHSD17B10ALOX15TSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1648 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3623372-B1 PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS VALO HEALTH INC (US) 2026-02-04 EP claimed
US-20250353821-A1 BENZENE SULFONAMIDE THIAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCERS INST NAT SANTE RECH MED (FR) 2025-11-20 US claimed
EP-4301736-B1 MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS LEAD DISCOVERY CENTER GMBH (DE) 2025-10-08 EP claimed
EP-4619106-A2 TREATMENT OF ASCT2-DEPENDENT CANCERS Neupharma, Inc (US) 2025-09-24 EP claimed
CN-119798223-A (1H-indazol-5-yl) amino-2-pyridine derivative and application thereof 沈阳药科大学 2025-04-11 CN claimed
US-20240415819-A1 MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS QLi5 Therapeutics AG (DE) 2024-12-19 US claimed
CN-118897041-A Method for detecting illegal addition of pyrimidinone ketobenzene compound in food and application thereof 山西省检验检测中心(山西省标准计量技术研究院) 2024-11-05 CN claimed
EP-4452956-A1 BENZENE SULFONAMIDE THIAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCERS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2024-10-30 EP claimed
CN-118574812-A Benzenesulfonamide thiazole compounds and their use for the treatment of cancer 国家医疗保健研究所 2024-08-30 CN claimed
WO-2024107753-A2 TREATMENT OF ASCT2-DEPENDENT CANCERS NEUPHARMA, INC (US) 2024-05-23 WO claimed
WO-1998042670-A1 NOVEL PYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ASTRA PHARMACEUTICALS LTD. (GB) 1998-10-01 WO claimed
WO-1998007742-A1 SULFONAMIDES ZENECA LIMITED (GB) 1998-02-26 WO claimed
WO-1998002438-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 1998-01-22 WO claimed
WO-1998002437-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 1998-01-22 WO claimed
US-5635510-A TACHYKININ (ESPECIALLY SUBSTANCE P AND NEUROKININ A) ANTAGONISTS; ANTIINFLAMMATORY AGENTS, ANALGESICS; NERVOUS SYSTEM DISORDERS; BRONCHODILATOR AGENTS MERRELL PHARMACEUTICALS INC. (US) 1997-06-03 US claimed
EP-0737204-A1 CS-1 PEPTIDOMIMETICS, COMPOSITIONS AND METHODS OF USING THE SAME CYTEL CORPORATION (US) 1996-10-16 EP claimed
WO-1995015973-A1 CS-1 PEPTIDOMIMETICS, COMPOSITIONS AND METHODS OF USING THE SAME CYTEL CORPORATION (US) 1995-06-15 WO claimed
EP-0272583-B1 5-SUBSTITUTED AMINO-4-HYDROXY-PENTENOIC ACID DERIVATIVES AND THEIR USE Banyu Pharmaceutical Co., Ltd. (JP) 1993-09-15 EP claimed
EP-0375451-A2 Compounds having a renin-inhibiting activity BEECHAM GROUP PLC (GB) 1990-06-27 EP claimed
US-4122265-A APPETITE SUPPRESSANTS HOFFMANN-LA ROCHE INC. (US) 1978-10-24 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250353821-A1 BENZENE SULFONAMIDE THIAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCERS HSPA5, HSP90B1, BAD KDM4E 2119/4885HSD17B10 3388/4885ALOX15 3099/4885
US-20240415819-A1 MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS PSMB5, PSMA5, PSMB1 KDM4E 1700/4885HSD17B10 2032/4885ALOX15 1921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.